Welcome, Guest
Username: Password: Remember me
CYTX Financial performance development
  • Page:
  • 1

TOPIC: PPS pressure in booming market

PPS pressure in booming market 17 Dec 2013 06:09 #1137

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3238
  • Thank you received: 1101
A friend mailed me the most likely reason for the pressure on the stock price in the past couple of days- could go even further I guess- :cry:

It looks like the IBB fund will be selling around 800,000-900,000 shares of stock and then some more by the closet indexers and the levered indexers. That is the most likely reason the stock is down today. This is the bottom group of market caps in the IBB that will all be coming out of the index

CYTX CYTORI THERAPEUTICS INC 0.05 $1,886,303 US23283K1051 XNMS Biotechnology 1.00
SIGA SIGA TECHNOLOGIES INC 0.04 $1,688,779 US8269171067 XNMS Biotechnology 1.00
ARQL ARQULE INC 0.04 $1,431,918 US04269E1073 XNMS Biotechnology 1.00
ONTY ONCOTHYREON INC 0.03 $1,190,627 US6823241087 XNMS Biotechnology 1.00
FOLD AMICUS THERAPEUTICS INC 0.03 $1,104,973 US03152W1099 XNMS Pharmaceuticals 1.00
GTXI GTX INC 0.03 $1,020,468 US40052B1089 XNMS Biotechnology 1.00
VICL VICAL INC 0.02 $984,415 US9256021042 XNMS Biotechnology 1.00
AVEO AVEO PHARMACEUTICALS INC 0.02 $971,070 US0535881090 XNGS Pharmaceuticals 1.00
ENZN ENZON PHARMACEUTICALS INC 0.02 $738,699 US2939041081 XNGS Pharmaceuticals 1.00

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire
The NASDAQ OMX Group, Inc.
NEW YORK, Dec. 16, 2013 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 23, 2013.
The following 21 securities will be added to the Index: AcelRx Pharmaceuticals, Inc. (ACRX), Agios Pharmaceuticals, Inc. (AGIO), BioCryst Pharmaceuticals, Inc. (BCRX), bluebird bio, Inc. (BLUE), ChemoCentryx, Inc. (CCXI), Cempra, Inc. (CEMP), Chimerix, Inc. (CMRX), Epizyme, Inc. (EPZM), Esperion Therapeutics, Inc. (ESPR), Horizon Pharma, Inc. (HZNP), Cellular Dynamics International, Inc. (ICEL), Insys Therapeutics, Inc. (INSY), KYTHERA Biopharmaceuticals, Inc. (KYTH), OncoMed Pharmaceuticals, Inc. (OMED), Onconova Therapeutics, Inc. (ONTX), Prothena Corporation plc (PRTA), PTC Therapeutics, Inc. (PTCT), Portola Pharmaceuticals, Inc. (PTLA), Regulus Therapeutics Inc. (RGLS), Sagent Pharmaceuticals, Inc. (SGNT) and Verastem, Inc. (VSTM).
The Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market(R) (NASDAQ(R)) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
As a result of the re-ranking, the following 16 securities will be removed from the Index: ArQule, Inc. (ARQL), AVEO Pharmaceuticals, Inc. (AVEO), Cytori Therapeutics, Inc. (CYTX), Enzon Pharmaceuticals, Inc. (ENZN), Amicus Therapeutics, Inc. (FOLD), Furiex Pharmaceuticals, Inc. (FURX), GTx, Inc. (GTXI), Hyperion Therapeutics, Inc. (HPTX), Oncothyreon Inc. (ONTY), Pain Therapeutics, Inc. (PTIE), QLT Inc. (QLTI), SIGA Technologies, Inc. (SIGA), Santarus, Inc. (SNTS), Targacept, Inc. (TRGT), Vical Incorporated (VICL) and ViroPharma Incorporated (VPHM).
The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index(SM) Fund (IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges.
The following user(s) said Thank You: rothco619, joeycav11

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

PPS pressure in booming market 17 Dec 2013 08:26 #1140

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2708
  • Thank you received: 199
Should add to Calhouns bonus...right ? LOL !

May also reduce some short interest

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.103 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites